Bioshares Biotechnology Clinical Trials Fund ETF Forecast

Buy or Hold candidate since Jun 08, 2026 Gain 17.21%

The BioShares Biotechnology Clinical Trials ETF price gained 5.43% on the last trading day (Monday, 22nd Jun 2026), rising from $45.47 to $47.94. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the ETF fluctuated 3.02% from a day low at $46.55 to a day high of $47.96. The price has risen in 8 of the last 10 days and is up by 17.9% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 39 thousand more shares were traded than the day before. In total, 61 thousand shares were bought and sold for approximately $2.94 million.

The ETFis at the upper part of a wide and horizontal trend and normally this may pose a good selling opportunity but a break-up through the top trend line at $48.15 will give a strong buy signal and a trend shift could be expected. Given the current horizontal trend, you can expect BioShares Biotechnology Clinical Trials ETF with a 90% probability to be traded between $41.24 and $48.73 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and ETFS seldom manage to go directly from the bottom of a trend up to the top. ETFS turning up in the middle of a horizontal trend are therefore considered to be potential runners.

BBC Signals & Forecast

The BioShares Biotechnology Clinical Trials ETF holds buy signals from both short and long-term Moving Averages giving a positive forecast for the ETF. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $44.29 and $43.37. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Tuesday, May 19, 2026, and so far it has risen 18.25%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.

Support, Risk & Stop-loss for BioShares Biotechnology Clinical Trials ETF

BioShares Biotechnology Clinical Trials finds support from accumulated volume at $46.00 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This ETF has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the ETF moved $1.41 between high and low, or 3.02%. For the last week, the ETF has had daily average volatility of 3.09%.

Our recommended stop-loss: $45.56 (-4.97%) (This ETF has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 22 days ago.)

Trading Expectations (BBC) For The Upcoming Trading Day Of Tuesday 23rd

For the upcoming trading day on Tuesday, 23rd we expect BioShares Biotechnology Clinical Trials Fund to open at $47.48, and during the day (based on 14 day Average True Range), to move between $47.23 and $48.65, which gives a possible trading interval of +/-$1.42 (+/-3.01%) up or down from last closing price. If BioShares Biotechnology Clinical Trials Fund takes out the full calculated possible swing range there will be an estimated 3.01% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $46.00, some $1.94 (4.05%) from the current price of $47.94, our system finds the risk reward attractive.

Is BioShares Biotechnology Clinical Trials Fund ETF A Buy?

BioShares Biotechnology Clinical Trials holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this ETF since the last evaluation from a Buy to a Hold candidate.

Current score: 0.000 Hold/Accumulate Downgraded

Zero in score indicates that our system is expecting high volatility and risk for the following trading day. Given the latest developments, we cannot determine the next direction as it may go both ways.

Predicted Fair Opening Price

Predicted fair opening price on June 23, 2026 - $47.48 ( 0.96%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk